We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
pharmaceuticals: Archive
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDPositive Net Change ANIPNegative Net Change ITCINegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDPositive Net Change PCRXPositive Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSNegative Net Change
pharmaceuticals
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
RDYPositive Net Change LGNDPositive Net Change ANIPNegative Net Change BBIONegative Net Change
earnings medical pharmaceuticals
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
SNYPositive Net Change BIIBPositive Net Change LGNDPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Bear of the Day: CVS Health (CVS)
by Jeremy Mullin
CVS continues to face headwinds amidst growth challenges.
CVSNegative Net Change WBANegative Net Change
pharmaceuticals retail
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
ABTNegative Net Change JNJPositive Net Change COPNegative Net Change NFLXPositive Net Change TSLANegative Net Change TTEPositive Net Change
auto-tires-trucks consumer-discretionary pharmaceuticals
A Look at Pharma ETFs Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
BMYNegative Net Change JNJPositive Net Change MRKNegative Net Change LLYNegative Net Change PJPPositive Net Change IHEPositive Net Change XPHPositive Net Change PPHPositive Net Change FTXHNegative Net Change
earnings etfs pharmaceuticals
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
LGNDPositive Net Change ANIPNegative Net Change APLSNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
ANIPNegative Net Change ADVMNegative Net Change ARVNNegative Net Change ABSINegative Net Change
biotechnology biotechs pharmaceuticals
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
by Kinjel Shah
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
TEVAPositive Net Change PRGOPositive Net Change ACADNegative Net Change IOVANegative Net Change VTRSPositive Net Change
biotechs pharmaceuticals
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change VTRSPositive Net Change
biotechs medical pharmaceuticals
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change LGNDPositive Net Change ANIPNegative Net Change RARENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
AZNPositive Net Change QCOMPositive Net Change HALNegative Net Change AIGNegative Net Change FDXNegative Net Change BKRNegative Net Change
computers pharmaceuticals transportation
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
JNJPositive Net Change PFEPositive Net Change NVONegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYPositive Net Change AMRNNegative Net Change ANIPNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
LGNDPositive Net Change ANIPNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
AMRNNegative Net Change ANIPNegative Net Change BHCNegative Net Change AMRXPositive Net Change
earnings medical pharmaceuticals
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
LGNDPositive Net Change ZTSNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
UTHRNegative Net Change LGNDPositive Net Change CORTPositive Net Change ANIPNegative Net Change
pharmaceuticals
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
MRKNegative Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYNegative Net Change LGNDPositive Net Change SRPTNegative Net Change ANIPNegative Net Change
biotechs gene-therapy medical pharmaceuticals